Artificial intelligence accelerates drug discovery and clinical testing

Artificial intelligence is transforming the pharmaceutical research and development landscape by analyzing vast biological datasets to identify connections between diseases and molecules. This technology aims to accelerate the drug discovery process by predicting which molecules are most likely to be effective therapeutic candidates.

According to Nature Medicine, AI-driven drug discovery has progressed into human testing phases. A notable example includes an AI-designed drug for idiopathic pulmonary fibrosis, which has reached phase 2a clinical trials. While AI can assist in identifying new therapeutic targets and molecules, researchers emphasize that candidates must still undergo rigorous laboratory verification and clinical trials to ensure safety and efficacy. Experts warn that AI results must be interpreted carefully, as models depend heavily on the quality and representation of their training data.